Navigation Links
Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
Date:4/14/2008

SAN DIEGO and SUNNYVALE, Calif., April 14 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today presented results from its preclinical program evaluating PCI-32765, an orally available, selective inhibitor of Bruton's tyrosine kinase, or Btk, in B-cell receptor (BCR) modulated diseases such as lymphomas and autoimmune diseases. The data were presented during the Annual Meeting of the American Association for Cancer Research (AACR) being held this week in San Diego, CA.

Researchers conducted studies with PCI-32765 examining the downstream signaling events in the BCR signal transduction pathways. In vitro drug treatment of B-cell lymphomas blocked BCR mediated signaling and in vivo drug treatment of lymphoma-bearing animal models resulted in inhibition of tumor growth. Normal human B-cell activation was also shown to be inhibited by drug treatment in vitro. PCI-32765 also showed significant activity in animal models of arthritis.

"These studies highlight the importance of Btk in immune mediated diseases," said Joseph J. Buggy, Ph.D., vice president of research for Pharmacyclics. "Further, these data support our ongoing IND-enabling studies for PCI-32765, and our plans for an anticipated clinical trial later this year."

B-cells are a type of white blood cell that normally play a key role in the body's immune response. However, when B-cells are overactive, the immune system produces inflammatory cells and antibodies that begin to attack the body's own tissue, leading to autoimmune diseases such as rheumatoid arthritis. Most lymphomas are caused by uncontrolled growth of B-cells. Btk is an enzyme that plays a crucial role in B-cell activation and inhibition of its function may be useful in the treatment of immune mediated diseases.

"These data, along with the additional results reported at AACR with our other drug candidates, demonstrate the breadth of our product portfolio," said Richard A. Miller, M.D., president and CEO of Pharmacyclics.

About Pharmacyclics

Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and other serious diseases. The company is leveraging its small-molecule drug development expertise to build a pipeline in oncology and other diseases based on a wide range of targets, pathways and mechanisms. More information about the company, its technology, and products can be found at http://www.pharmacyclics.com. Pharmacyclics(R) and the "pentadentate" logo(R) are registered trademarks of Pharmacyclics, Inc.

NOTE: Other than statements of historical fact, the statements made in this press release about enrollment and future plans for our clinical trials, progress of and reports of results from preclinical and clinical studies, clinical development plans and product development and corporate partnering activities are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. The words "project," "believe," "will," "may," "continue," "plan," "expect," "intend," "anticipate," variations of such words, and similar expressions also identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. The forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements. Factors that could affect actual results include risks associated with unexpected delays in clinical trials and preclinical studies and the timing for making related regulatory filings; the fact that data from preclinical studies and Phase 1 or Phase 2 clinical trials may not necessarily be indicative of future clinical trial results; our ability to estimate accurately the amount of cash to be used to fund operations over the next 12 months, our ability to obtain future financing and fund the product development of our pipeline; the initiation, timing, design, enrollment and cost of clinical trials and preclinical studies; our ability to establish successful partnerships and collaborations with third parties; the regulatory approval process in the United States and other countries; and our future capital requirements. For further information about these risks and other factors that may affect the actual results achieved by Pharmacyclics, please see the company's reports as filed with the U.S. Securities and Exchange Commission from time to time, including but not limited to its annual report on Form 10-K for the period ended June 30, 2007 and its subsequently filed quarterly reports on Form 10-Q. Forward-looking statements contained in this announcement are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
2. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
3. Genzyme Genetics Announces Launch of Carrier Testing and Prenatal Diagnosis for Spinal Muscular Atrophy
4. Perrigo Announces Approval for Over-the-Counter Childrens Cetirizine Oral Solution
5. Nuvelo Announces Preclinical Data for NU206 Demonstrating Potent Therapeutic Activity in Oral Mucositis Models
6. Napo Announces Successful Clinical Results in Phase 2 Study of Crofelemer in Acute Adult Infectious Diarrhea
7. Antipodean Pharmaceuticals Announces Completion of Phase 2 Study of Lead Compound MitoQ(R)
8. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007
9. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
10. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722
11. Favrille Announces Data Cutoff for Phase 3 Registration Trial of Specifid; Data Analysis and Unblinding Expected in June
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... WILMINGTON, N.C. , Aug. 15, 2017 ... Wilmington, NC , today announced that the company ... at the University of North Carolina at Chapel Hill ... AccuKit-HIV is designed to characterize and quantify HIV reservoir ... and after pharmacological intervention. The HIV Cure Center is ...
(Date:8/14/2017)... and PETACH TIKVAH, Israel ... (NASDAQ: BCLI), a leading developer of adult stem cell ... second quarter ending June 30, 2017. ... of preparing for our pivotal Phase 3 trial to ... Lebovits , President and Chief Executive Officer of BrainStorm. ...
(Date:8/10/2017)... Aug. 10, 2017  Physical Rehabilitation Network (PRN), acquired the ... Lakewood, Colorado . The reputable clinic will continue ... PT, DPT with his staff of four clinicians. Lipkin received ... and brings over 10 years of experience with a strong ... Belmar PT marks the 10th PRN clinic in and around the ...
Breaking Medicine Technology:
(Date:8/22/2017)... ... ... of the past six years, Lightning Labels has sent out a call for users of ... variety and creativity of their designs. Submissions this year were open from May 18 to ... announce the winners of the sixth annual Photo Contest, along with the prizes they've received:, ...
(Date:8/22/2017)... ... ... Star Glass is new to the Texas market, but is proudly managed by widely recognized ... and models, in Grand Prairie, TX, located in the center of the DFW Metroplex, the ... business for the past 40 years with 32 convenient locations in Texas, Nevada and California ...
(Date:8/22/2017)... ... August 22, 2017 , ... “Without Love’s Beauty and ... and the struggles faced while hoping for a better life. “Without Love’s Beauty ... Von Bernewitz, who spent 13 years working with deprived/neglected adolescents and almost 20 ...
(Date:8/22/2017)... ... August 22, 2017 , ... John Stewart ... and Managing Member for t4 Leadership Development & Consulting. He has spent his ... of “success”: physician leadership development, servant leadership, data driven process improvement, and supportive ...
(Date:8/22/2017)... ... 22, 2017 , ... Although Labor Day is not as popular for fireworks ... weekend displays, and numerous households celebrate the unofficial end of summer with backyard fireworks ... pets. , Kris Zambo, owner of Dynamite Fireworks in Hammond, Indiana, ...
Breaking Medicine News(10 mins):